Targeted Medical Pharma EBIT per Share
The EBIT per Share of Targeted Medical Pharma (TRGM) as of Aug 5, 2026 is -0.07 USD. In the previous year, EBIT per Share was -0.10 USD — a change of -24.09% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.07USD
YoY
-24.09%
Last updated:
EBIT per Share of Targeted Medical Pharma is 2026 -0.07 USD. EBIT per Share of Targeted Medical Pharma was 2025 -0.10 USD. It decreases by -24.09% higher compared to the previous year.
Access this data via the Eulerpool API
Targeted Medical Pharma Stock analysis
What does Targeted Medical Pharma do? Targeted Medical Pharma Inc is a California-based biotechnology company that focuses on the development and marketing of patented pharmaceutical products in the field of neuroscience and pulmonology. The company was founded in 1999 and has since placed emphasis on the development of patented pharmaceutical products that can be used in various medical areas.
The main business model of Targeted Medical Pharma is to bring innovative product developments to the market that can bridge the gap between conventional medicine and integrative medicine. The company aims to create therapy options that are very specific to certain diseases, which can then be patented and marketed. However, disposable drugs (medicines that need to be administered once a year and then have long-term effects), as one knows from other companies, are not used.
The company offers a wide range of different divisions and products that have been developed over the years. The main divisions covered by Targeted Medical Pharma include:
1. Neurology: Here, the company develops products for the treatment of neurological disorders such as ADHD, Alzheimer's, autism, depression, stroke, and other diseases of the central nervous system.
2. Pain management: In this division, Targeted Medical Pharma focuses on the development of products against chronic pain, back pain, and migraines.
3. Sports medicine: The goal of this division is to help athletes improve their performance and recovery and to prevent injuries.
4. Pulmonology: Here, Targeted Medical Pharma offers products targeting the treatment of lung problems such as asthma and COPD.
Some of the well-known products developed by Targeted Medical Pharma include:
1. Sentra AM: A dietary supplement specifically developed to support the nervous system and used for the treatment of depression, anxiety, and other neurological disorders.
2. Theramine: A patented amino acid mixture developed for chronic pain, supporting the body in pain relief and fighting inflammation.
3. Aeropur: An inhalation device specifically developed for the treatment of asthma and COPD.
4. Clearwayz: A solution that helps loosen mucus and clear airways during colds and bronchitis.
5. Trepadone: A dietary supplement developed in collaboration with the US Navy to reduce inflammation and muscle soreness after intense physical training and improve recovery.
The company has earned great respect in the industry and among investors, particularly through the continuous development of new products and emphasis on scientific research and clinical evidence. A seven-figure number of patients can benefit from these innovations. Targeted Medical Pharma has worked on the development of more than 25 different patented pharmaceutical products, several of which have already been approved by the FDA (Food and Drug Administration). The company has also established numerous valuable connections with academic institutions and healthcare facilities, which is expected to benefit the development of new and innovative products.
Overall, Targeted Medical Pharma is a company specializing in patented product development. In fact, it is working hard to revolutionize the complementary medicine field by creating innovative therapies and treatments to have a lasting positive impact on the health and well-being of millions of people worldwide. Targeted Medical Pharma is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Targeted Medical Pharma stock
EBIT per Share of Targeted Medical Pharma is -0.07 USD in 2026.
EBIT per Share of Targeted Medical Pharma changed from -0.10 USD to -0.07 USD, representing a -24.09% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Targeted Medical Pharma since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Targeted Medical Pharma
All Key Metrics — Targeted Medical Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth